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Abstract
Colorectal cancer (CRC) is the third greatest cancer burden in the United States. The
remarkably diverse Mountain West state of Nevada has uncharacteristically high CRC mor-
tality compared to other Western states. We aimed to study the determinants of the CRC
excess burden by using data from the Nevada Central Cancer Registry from 2003–2013.
Five-year cause-specific age-adjusted survival from colorectal cancer was calculated and
stratified by sex, race/ethnicity and region of Nevada. Cox Proportional Hazards regression
modelling was used to study the impact of demographic, social, and clinical factors on CRC
survival in Nevada, assessing follow-up as accurately as possible. The extent to which dif-
ferences in survival can be explained by receipt of stage-appropriate treatment was also
assessed. 12,413 CRC cases from 2003–2013 in Nevada were analyzed. Five-year CRC
survival was low: 56.0% (95% CI: 54.6–57.5) among males and 59.5% (95% CI: 58.0–61.1)
among females; significantly lower than national 5-year survival of 65.1% and 66.5%,
respectively. Low survival was driven by populous Southern Nevada; after adjustment for all
covariates, Southern Nevadans were at 17% higher risk of death than their counterparts in
Northwestern Nevada (HR:1.17; 95% CI:1.08–1.27). Many patients did not receive stage-
appropriate treatment, although this only partly explained the poor survival, uniformly low for
every race/ethnicity in Nevada. The observed disparity for this one state within a single
nation merits public health attention; regardless of the state or region of residence, all Ameri-
cans deserve equal opportunity for optimum health outcomes in the face of a cancer diagno-
sis. The current study provides baseline information critical to clinicians, public health
professionals, and all relevant stakeholders as they attempt to discern why Nevada’s out-
comes are vastly divergent from its neighboring Western states and make plans for
remediation.
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Introduction
Colorectal cancer (CRC) is the third leading cause of cancer incidence and mortality among
both men and women in the United States (US) [1], with an estimated 145,600 new cases and
51,000 deaths expected in 2019 [1]. It currently accounts for between 8–9% of all US cancer
cases and deaths [2]. While rate declines in mortality have been seen in recent decades, attrib-
utable both to improvements in treatment and to the increased reach of CRC screening on a
population basis [3], the CRC burden across the US—as measured by incidence, survival, and
mortality—is not distributed uniformly. Disparities are seen by race/ethnicity, sex, socioeco-
nomic status, and geography. Non-Hispanic black and American Indian/Alaskan Native pop-
ulations suffer disproportionately high CRC incidence and mortality compared to non-
Hispanic whites; in aggregate, Hispanics and Asian/Pacific Islanders (API) fare better [3].
Rural populations as well as those with low socioeconomic status shoulder a higher burden [4–
6] and have benefitted least from advances in screening and treatment [7, 8]. Broad trends
across the US suggest that the highest CRC burden is seen in the Southeast and the lowest is
seen in the Western region of the United States [9].
The Mountain West state of Nevada is a unique state, the 7th largest by land area, comprised
of only two large metropolitan areas and vast swaths of rural and frontier lands. The current
population of almost 3 million reflects tremendous population growth, over 50% since 2000
[10], contributing to Nevada’s strikingly diverse profile. Approximately half of Nevada’s popu-
lation identifies as minority, including 10% non-Hispanic black, 9% Asian/Pacific Islander,
and 30% Hispanic [10]. Moreover, 20% of Nevada’s population is foreign-born, ranking fifth
of all states [10]; it also leads all other states in the proportion of its total population that is
undocumented: approximately 7% [11]. In addition to the unique geographic and demo-
graphic profile, Nevada consistently ranks low on two important social indicators of health:
education [12] and health insurance coverage [13].
According to known cancer patterns, Nevada stands as an exception, with an uncharacteris-
tically high CRC mortality rate compared to any Western state, including its five neighbors:
Arizona, California, Idaho, Oregon, and Utah [3]. However, to date, only one outdates study
attempted to characterize CRC survival in Nevada [14].
Therefore, this study aims to accurately characterize colorectal cancer survival in Nevada by
race/ethnicity, sex, stage at diagnosis, and region of Nevada, and compare with national sur-
vival. We also aim to identify within-state survival disparities and examine the impact of avail-
able demographic, social, and clinical factors on CRC survival. Owing to its rapidly increasing
population, understanding what drives Nevada’s unfavorable CRC profile is critical to meeting
the cancer control and prevention needs of Nevada’s burgeoning and racial/ethnically diverse
population.
Methods
The Institutional Review Board at the University of Nevada, Las Vegas reviewed this study,
#858093–1, and determined it was exempt. All data were de-identified.
All cases of first primary colorectal cancer, inclusive of International Classification of Dis-
eases for Oncology (ICD-O-3) codes C18-C20 [15], diagnosed in the state of Nevada between
2003–2013 (all years available at time of study) were included in this project; excluded cases
were those diagnosed by death certificate or autopsy only (n = 306), as well as cases with a neg-
ative or missing survival period (n = 17). Data were obtained from the Nevada Central Cancer
Registry (NCCR), which collects all cancer incidence data in Nevada using standards estab-
lished by the Centers for Disease Control and Prevention’s National Program of Cancer Regis-
tries [16] and the North American Association of Central Cancer Registries [17]. To minimize
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the number of missing deaths, customary death record linkages with the Nevada Office of
Vital Records were augmented by linkage with the National Death Index [18]. For comparison
with national survival, CRC survival for the same time period was derived from the National
Cancer Institute’s Surveillance, Epidemiology, and End Results Program (SEER) data. SEER-
18 covers approximately 28% of the US population, and is fairly representative of the entire US
cancer population; it does not contain Nevada data [19].
Covariates included demographic, social, and clinical factors ascertained at date of diagno-
sis and assessed for their impact on colorectal cancer survival. Age was categorized into the fol-
lowing five groups: 15–44, 45–54, 55–64, 65–74, and 75+, according to the International
Cancer Survival Standards age classification [20]. Cases were classified into six mutually exclu-
sive racial/ethnic groups: non-Hispanic white, non-Hispanic black, Hispanic, American
Indian/Alaska Native (AI/AN), Filipino, and other API (Chinese, Japanese, Korean, Indian,
etc.). Filipinos were considered separately from other APIs as they accounted for 67% of Neva-
da’s overall API population in 2010 [21]. Place of residence in Nevada was divided into three
distinct geographic regions. Southern Nevada is comprised of populous Clark County, which
includes Las Vegas and the surrounding areas. The Northwestern Nevada region represents
the only other large population area in NV, encompassing the capital, Carson City, as well as
Douglas, Lyon, Storey, and Washoe counties. The remaining eleven sparsely populated rural
and frontier counties were classified as Rural Nevada.
Social factors included were insurance type, marital status, and socioeconomic status (SES).
Insurance categories included private, Medicare, Medicaid, uninsured, and unknown. Marital
status categories were married, single, divorced/separated, widowed, or unknown. Since SES
information is not directly collected on individual patients by the NCCR, the proportion of
people living in poverty in 2011 in a patient’s zip code of residence at diagnosis was used as a
proxy for SES; less than 5% poverty in zip code of residence was considered high SES, between
5–10% was medium SES, and over 10% was low SES.
Tumor stage at diagnosis was coded I, II, III, or IV, according to guidelines set by the Amer-
ican Joint Committee on Cancer [22]. However, for comparison with national survival esti-
mates, SEER Summary Staging of localized, regional, and distant groups was used [23].
Anatomic sublocations considered were right colon (C18.0–18.3), left colon (C18.4–18.7),
colon NOS (C18.8, C18.9) and rectum (C19.9, 20.9). Morphologies included adenocarcinomas
(ADKs), ADKs in adenoma/polyp, Mucinous ADKs, Carcinoids, and Carcinoma NOS.
Receipt of stage-appropriate treatment was determined only for AJCC Stage I-III tumors by
assessing whether treatments (radiation, chemotherapy and/or surgery) were received in
accordance with guidelines developed by The American Society of Colon and Rectal Surgeons
[24, 25], as presented in Table 1. Cases with missing information for any treatment variable
required for determination of stage-appropriate treatment were considered Unknown. Stage
Table 1. Minimum requirements for consideration as having received stage-appropriate treatmenta for AJCC
Stages I-III.
Stage at Diagnosis Colon Cancer Rectal Cancer
C18 (all) C19.9 & C20.9
AJCC I surgery Surgery
AJCC II surgery surgery, radiotherapy & chemotherapy
AJCC III surgery & chemotherapy surgery, radiotherapy & chemotherapy
Abbreviation: AJCC, American Joint Committee on Cancer.
a. Guidelines developed by The American Society of Colon and Rectal Surgeons.
https://doi.org/10.1371/journal.pone.0221337.t001
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IV tumors were excluded for this sub-analysis since registry data does not distinguish whether
treatments are used for palliative or curative intent.
Five-year cause-specific age-adjusted survival from colorectal cancer was calculated and
stratified by sex, race/ethnicity (all-stages-combined), and region of Nevada (all-stages-com-
bined and stage-specific), using the life table method. Survival time was measured in months
from the date of diagnosis until either the date of death or the end of the study period, Dec 31,
2014, whichever occurred first. The presumed alive assumption [26] was used for censored
observations; cases dead from another cause prior to the end of the study were censored. Sur-
vival from SEER-18 data was computed using the presumed alive option for comparability
with Nevada survival.
Kaplan-Meier survival curves were developed to visualize differences in survival within the
state of Nevada by stage at diagnosis (SEER summary staging), period of diagnosis (2003–2007
and 2008–2012), race/ethnicity, and region of Nevada. Log-rank tests were used to detect dif-
ferences in survival curves.
To calculate comparative risk of death and identify factors impacting survival, Cox propor-
tional hazards regression models for multivariate survival analysis were constructed, adjusting
for all covariates significant in univariate analyses. Hazard ratios and their corresponding 95%
confidence intervals (CI) were computed. Separate models were constructed for the sub-analy-
sis to examine risk of CRC death for cases diagnosed in AJCC stages I-III (with complete infor-
mation on treatments) by region of Nevada and receipt of stage-appropriate treatment.
Statistical tests were interpreted as significant against α = 0.05. Data were analyzed with
SPSS v22 and SAS 9.3.
Results
In the 11-year period of 2003–2013, first primary colorectal cancer tumors were identified in
12,413 patients from the Nevada Central Cancer Registry. Fifty-five percent of patients were
male, 61% were over 65 years of age, 78% were non-Hispanic white and two-thirds were from
Southern Nevada. Almost half were married; 73% had either private insurance or Medicare.
Over 90% of tumors were some type of ADK; distribution between right colon, left colon, and
rectum was approximately equal but almost 10% were colon NOS cases. For the sub-analysis,
68% of tumors (n = 8480) were diagnosed in AJCC Stages I, II, or III; of those, only 36%
received stage-appropriate treatment, while 39% did not. For 26% of these cases, stage-appro-
priate treatment was unable to be determined due to missing treatment information (Table 2).
As expected, Kaplan Meier curves showed significantly better survival from CRC in Nevada
for tumors diagnosed in localized and/or regional stages (p< .001). Moreover, survival was
slightly higher in the more recent 2008–2012 time period than in 2003–2007 (p = .007). Signifi-
cant survival differences were also seen for race/ethnicity and region of Nevada (Fig 1).
Five-year age-adjusted colorectal-cancer-specific survival in Nevada was 56.0% (95% CI:
54.6–57.5) among males, significantly lower than females at 59.5% (95% CI: 58.0–61.1); both
were significantly lower than corresponding national proportions of 65.1% and 66.5% based
on the SEER-18 catchment area for the same time period. Within Nevada, non-Hispanic black
males had the lowest survival of any analyzed group, at 48.3% (95% CI: 42.7–53.9), and Other
API females had the highest at 68.8% (95% CI: 61.6–76.0). However, for every distinct male
racial/ethnic group, CRC survival in Nevada was significantly lower than CRC survival of their
counterparts nationally. Likewise, non-Hispanic white and Hispanic females had significantly
lower survival compared to SEER-18 CRC patients of the same race/ethnicity (Table 3).
Examining by stage at diagnosis, five-year CRC survival in the entire state of Nevada for
localized and regional stage tumors was significantly lower than national survival. Males and
Low colorectal cancer survival in the Mountain West state of Nevada
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Table 2. Characteristics of 12,413 colorectal cancer cases from 2003–2013 in Nevada.
DEMOGRAPHIC FACTORS N %
Sex Male 6817 54.9
Female 5596 45.1
Age Group 16–44 years old 583 4.7
45–54 years old 1519 12.2
55–64 years old 2730 22.0
65–74 years old 3589 28.9
75+ years 3992 32.2
Race/Ethnicity Non-Hispanic white 9674 77.9
Non-Hispanic black 927 7.5
Hispanic 1041 8.4
Filipino 220 1.8
Other Asian/Pacific Islander 467 3.8
American Indian/Alaskan Native 84 0.7
Nevada Region Northwestern Nevada 2714 21.9
Southern Nevada 8223 66.2
Rural Nevada 1025 8.3
Unknown 451 3.6
SOCIAL FACTORS
Marital Status Married 6008 48.4
Single 1887 15.2
Divorced/Separated 1284 10.3
Widowed 1899 15.3
Unknown 1335 10.8
Insurance Status Private Insurance 4470 36.0
Medicare 4579 36.9
Medicaid 602 4.8
Uninsured 470 3.8
Unknown 2292 18.5
Socioeconomic Status High 2453 19.8
Intermediate 4222 34.0
Low 4878 39.3
Unknown 860 6.9
CLINICAL FACTORS
Stage at Diagnosis AJCC I 2429 19.6
AJCC II 2798 22.5
AJCC III 3253 26.2
AJCC IV 2097 16.9
Unknown 1836 14.8
Morphology Adenocarcinoma (ADK) 9614 77.5
ADK in adenoma/polyp 481 3.9
Mucinous ADK 1173 9.4
Carcinoids 307 2.5
Carcinoma NOS 838 6.8
Sublocation of Tumor Colon-Right 3902 31.4
Colon-Left 3767 30.3
Rectum 3588 28.9
Colon NOS 1156 9.3
(Continued)
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females in Nevada diagnosed with CRC at a localized stage had 5-year survival proportions of
83.3% and 86.7%, respectively, compared to national survival of 88.6% (males) and 90.0%
(females). Even larger survival differences were seen for males and females in Nevada diag-
nosed with CRC at a regional stage; 5-year survival was 61.9% and 63.2%, respectively, com-
pared to national survival of 69.9% (males) and 71.4% (females). Survival for distant stage
CRC tumors was not significantly different than national survival for either sex. Notably, by
geographic region of Nevada, stage-specific survival in Northwestern Nevada did not differ
from national survival at any stage for both men and women. Five-year CRC survival in
Table 2. (Continued)
DEMOGRAPHIC FACTORS N %
STAGE-APPROPRIATE TREATMENTa n = 8480 %
Received Yes 3028 35.7
No 3263 38.5
Unknownb 2189 25.8
Abbreviations: AJCC, American Joint Committee on Cancer; ADK, Adenocarcinoma; NOS, Not Otherwise Specified.
a. Restricted to AJCC Stages I,II,III;
b. Unable to make determination.
https://doi.org/10.1371/journal.pone.0221337.t002
Fig 1. Kaplan Meier CRC survival curves for select prognostic factors in Nevada. Survival differences by: A. stage at diagnosis B.
period of diagnosis C. race/ethnicity D. region of Nevada.
https://doi.org/10.1371/journal.pone.0221337.g001
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Southern Nevada was significantly lower than national survival for all diagnosis stages except
for distant stage in men (Table 4).
After adjustment for all clinical, social, and demographic covariates, as well as year of diag-
nosis, Cox proportional hazard model estimates indicated that female CRC patients were at
11% lower risk of death than male. Southern Nevadans were at 17% higher risk than their
counterparts in Northwestern Nevada (HR:1.17; 95% CI:1.08–1.27). By race/ethnicity, non-
Hispanic blacks and Filipinos did not differ significantly from non-Hispanic whites, while His-
panics and Other APIs had 14% and 25% significantly lower risk, respectively (HR: 0.86; 95%
CI: 0.77–0.97) and (HR: 0.75; 95% CI: 0.63–0.90). Patients with any insurance status type other
Table 3. Five-year age-adjusteda colorectal cancer survival by sex and by race/ethnicityb. Nevada compared to overall United Statesc. 2003–2013.
Male Female
Survival 95% CI Survival 95% CI
All race/ethnicities Overall US 65.1% (64.8–65.3) 66.5% (66.3–66.8)
Nevada 56.0% (54.6–57.5) 59.5% (58.0–61.1)
Non-Hispanic white Overall US 65.9% (65.6–66.2) 67.2% (66.9–67.5)
Nevada 59.3% (57.7–61.0) 59.9% (58.1–61.6)
Non-Hispanic black Overall US 56.0% (55.0–56.9) 60.3% (59.5–61.1)
Nevada 48.3% (42.7–53.9) 54.3% (48.6–60.1)
Hispanic Overall US 64.3% (63.4–65.1) 66.6% (65.6–67.4)
Nevada 57.0% (51.9–62.1) 56.0% (50.7–61.4)
Filipino Overall US 67.7% (65.5–69.7) 69.6% (67.4–71.6)
Nevada 46.1% (34.2–58.0) 63.2% (52.9–73.5)
Other API Overall US 69.3% (68.2–70.3) 70.0% (68.9–71.0)
Nevada 59.8% (52.1–67.6) 68.8% (61.6–76.0)
Abbreviations: API, Asian/Pacific Islander; CI, Confidence Interval; US, United States.
a. Adjusted according to International Cancer Survival Standard.
b. American Indian/Alaskan Native suppressed due to small numbers
c. SEER-18.
https://doi.org/10.1371/journal.pone.0221337.t003
Table 4. Five-year age-adjusteda all stage & stage-specific colorectal cancer survival by geographic region of Nevada compared to overall United Statesb. 2003–2013.
All Stages Localized Stage Regional Stage Distant Stage
MALE Survival 95% CI Survival 95% CI Survival 95% CI Survival 95% CI
Overall United Statesb 65.1% (64.8–65.3) 88.6% (88.3–88.8) 69.9% (69.4–70.4) 13.0% (12.5–13.4)
Nevada 56.0% (54.6–57.5) 83.3% (81.3–85.3) 61.9% (59.6–64.2) 11.8% (9.5–14.0)
Northwestern Nevada 58.8% (55.7–61.9) 85.2% (81.2–89.3) 64.8% (60.0–69.6) 15.2% (10.1–20.2)
Southern Nevada 55.8% (54.0–57.5) 82.3% (79.8–84.8) 61.8% (58.9–64.6) 10.2% (7.5–12.9)
Rural Nevadac 52.2% (47.0–57.4) - - - - - -
FEMALE
Overall United Statesb 66.5% (66.3–66.8) 90.0% (89.7–90.3) 71.4% (71.0–71.8) 15.2% (14.7–15.7)
Nevada 59.5% (58.0–61.1) 86.7% (84.5–88.8) 63.2% (60.8–65.7) 14.0% (11.3–16.7)
Northwestern Nevada 63.8% (60.6–67.0) 89.1% (85.1–93.1) 66.4% (61.3–71.6) 21.3% (15.0–27.7)
Southern Nevada 58.3% (56.4–60.2) 85.9% (83.3–88.6) 62.0% (59.0–65.0) 10.5% (7.4–13.5)
Rural Nevadac 58.4% (52.6–64.3) - - - - - -
a. Adjusted according to International Cancer Survival Standard.
b. SEER-18.
c. Rural data were too sparse to accurately calculate age-adjusted survival by stage.
https://doi.org/10.1371/journal.pone.0221337.t004
Low colorectal cancer survival in the Mountain West state of Nevada
PLOS ONE | https://doi.org/10.1371/journal.pone.0221337 August 19, 2019 7 / 15
than private insurance had higher risk of CRC death. Likewise, any marital status besides the
referent, married, conferred significantly higher risk of death. CRC mortality risk increased
inversely with socioeconomic status. For clinical factors, carcinoma NOS cases had 74% higher
risk than the referent ADK morphology. By tumor sublocation, patients with colon NOS cases
had an almost 50% higher risk of death than those with right-sided tumors, while risk of death
from a left-sided CRC tumor was lower than from a right-sided tumor (HR: 0.89; 95% CI:
0.82–0.97). Patients with metastatic CRC, AJCC stage IV, had a 14 times higher risk of death
than those with Stage I (Table 5).
Table 5. Demographic, social, and clinical determinants of CRC risk of deatha in Nevada, 2003–2013.
HR 95% CI
Sex Male referent
Female .89 (0.83–0.95)
Nevada Region Northwestern Nevada referent
Southern Nevada 1.17 (1.08–1.27)
Rural Nevada 1.11 (0.98–1.27)
Race/ Ethnicityb Non-Hispanic white referent
Non-Hispanic black 0.96 (0.86–1.09)
Hispanic 0.86 (0.77–0.97)
Filipino 0.92 (0.74–1.16)
Other Asian/Pacific Islander 0.75 (0.63–0.90)
Marital Status Married referent
Single 1.14 (1.04–1.25)
Divorced/Separated 1.26 (1.14–1.40)
Widowed 1.27 (1.15–1.40)
Insurance Status Private Insurance referent
Medicare 1.16 (1.07–1.27)
Medicaid 1.38 (1.20–1.59)
Uninsured 1.43 (1.24–1.66)
Socioeconomic Status High referent
Intermediate 1.22 (1.11–1.34)
Low 1.38 (1.26–1.52)
Stage at Diagnosis AJCC I referent
AJCC II 1.93 (1.67–2.24)
AJCC III 3.48 (3.03–3.99)
AJCC IV 14.44 (12.60–16.55)
Unknown 4.94 (4.23–5.76)
Morphology Adenocarcinoma (ADK) referent
ADK in adenoma/polyp 0.73 (0.57–0.92)
Mucinous ADK 1.06 (0.95–1.17)
Carcinoids 0.42 (0.31–0.57)
Carcinoma NOS 1.74 (1.53–1.99)
Sublocation of Tumor Colon-Right referent
Colon-Left 0.89 (0.82–0.97)
Rectum 0.98 (0.91–1.07)
Colon NOS 1.47 (1.31–1.65)
Abbreviations: ADK, Adenocarcinoma; AJCC, American Joint Committee on Cancer; CI, Confidence Interval; HR, Hazard Ratio; NOS, Not Otherwise Specified.
a. Multivariate Cox Proportional Hazards: Adjusted for all variables shown as well as age group and year of diagnosis.
b. American Indian/Alaskan Native suppressed due to small numbers.
https://doi.org/10.1371/journal.pone.0221337.t005
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In the sub-analysis, restricting analysis to Nevada’s CRC cases diagnosed in AJCC stages
I-III and adjusting for age, sex, race/ethnicity, and year of diagnosis, patients who were identi-
fied as not receiving stage-appropriate treatment had 2.47 times the risk of death (95% CI:
2.21–2.76) within 5 years than those who received stage-appropriate treatment. Moreover,
death from CRC at these stages after adjustment for stage-appropriate treatment was 14% and
28% significantly higher in Southern and Rural Nevada, (HR: 1.14; 95% CI: 1.01–1.29) and
(HR: 1.28; 95% CI: 1.03–1.58), respectively, than in the Northwestern region. (Table 6).
Discussion
Our study documented CRC survival disparities between the state of Nevada and the overall
US; the proportion of patients diagnosed with CRC that survived at least five years was much
lower in Nevada than the SEER-18 national survival. Based on a recent study of CRC survival
in 38 US states (Nevada not included) [27], our data suggest that, despite slight methodological
differences, survival from colorectal cancer in Nevada may be the lowest in the entire US.
Such a disparity for one state within a single nation merits public health attention; regardless
of the state of residence, all Americans deserve equal opportunity for optimum health out-
comes in the face of a cancer diagnosis. Thus, the current study provides baseline information
critical to clinicians, public health professionals, and all relevant stakeholders as they attempt
to discern why Nevada’s outcomes are vastly divergent from its neighboring Western states
and make plans for remediation.
The current study also documents for the first time that a striking within-state regional dis-
parity largely explains Nevada’s poor survival profile. The low CRC survival observed in popu-
lous Southern Nevada is driving the state’s overall poor survival profile; taken alone, CRC
survival in Northwestern Nevada is on par with national CRC survival. Unfortunately, a similar
regional survival disparity has previously been documented in Southern Nevada for breast can-
cer [28] and lung cancer [29]. Nevada’s disparate results from its Western neighbors is likely
related to shortages of medical training centers and physicians, especially in the densely popu-
lated Southern Nevada. Until the recent opening of the University of Nevada Las Vegas School
of Medicine in Fall 2017, Southern Nevada was the largest metropolitan area in the US without a
public medical school [30]. It also ranked 46th in the nation for rates of residency and fellowship
placements [31]. Despite a 10% increase in physician-per-capita rate from 2005–2015 [32],
Nevada ranked 48th - 49th of all US states for rates of active patient care physicians, active general
Table 6. Sub-analysis: Risk of deatha from CRC, restricted to AJCC stages I-III with known TAG status, by geo-
graphic region and TAG. Nevada, 2003–2013.
Model 1 Model 2
HR 95% CI HR 95% CI
Nevada Region
Northwestern Nevada Referent referent
Southern Nevada 1.20 (1.06–1.36) 1.14 (1.01–1.29)
Rural Nevada 1.37 (1.11–1.69) 1.28 (1.03–1.58)
Stage-Appropriate Treatment
Received referent
Did not receive - - 2.47 (2.21–2.76)
Abbreviations: AJCC, American Joint Committee on Cancer; CI, Confidence Interval; HR, Hazard ratio.
a. Multivariate Cox Proportional Hazards: Model 1 adjusted for sex, age group, race/ethnicity, and year of diagnosis.
Model 2 adjusted for all Model 1 variables and stage-appropriate treatment.
https://doi.org/10.1371/journal.pone.0221337.t006
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surgeons and active primary care physicians per capita in 2015 [31]. However, physician-per-
capita rates in Northwestern Nevada were 33% higher than in Southern Nevada [32]. Addition-
ally, while Southern Nevada comprises approximately 73% of Nevada’s total population [10], it
had only 53% of its radiation oncologists, 65% of its gastroenterologists, and 66% of its primary
care physicians in 2015, which may have limited access to screening and treatment [32]. Efforts
to recruit, train and retain medical professionals are urgently needed for Southern Nevada.
Particularly troubling from a clinical perspective was our finding in the sub-analysis that a
significant portion of Nevadans with colorectal cancer did not receive stage-appropriate treat-
ment, especially in Southern and Rural Nevada. Previous US studies have linked racial/ethnic
minorities, lack of insurance, and low socioeconomic status to lower likelihood of receiving
recommended cancer care according to guidelines [33]. In Nevada, future research should
clarify the reasons why some patients are not receiving guideline-recommended stage-specific
care. Reasons are likely complex and multi-faceted, including access to care, practice differ-
ences between physicians, patient amenability to treatment based on age and comorbidities,
and personal patient choices. If needed, modifications to colorectal cancer care protocols by
clinicians should be implemented. Interventions should be developed to reduce barriers to
receipt of quality care. Likewise, completeness and quality of cancer reporting, especially on
treatment variables, should be improved to facilitate development of a more comprehensive
picture of Nevada’s CRC survival profile.
One modifiable factor with the potential for leading to better CRC survival outcomes is
colon cancer screening on a population basis, as it can detect tumors at earlier stages [34].
Screening can also prevent malignancies through the detection and removal of pre-cancerous
polyps [34]. However, in Nevada, prevalence of CRC screening for 2002–2010, a reasonable
approximation for our study period, was just 58%, ranking 45th out of 50 states, and well
below the national CRC screening prevalence at that time of 65% [35]. Moreover, and likely
contributing to the within-state survival disparities seen here, CRC screening uptake differs
between the geographic regions of Nevada. Behavioral Risk Factor Surveillance System
(BRFSS) estimates show that, similar to national trends, CRC screening in the Reno Metropoli-
tan Statistical Area, (approximating Northwestern Nevada), increased from 49% in 2002 to
69% in 2012. However, the Las Vegas Metropolitan Statistical Area, (approximating Southern
Nevada), only increased from 46% to 59% [36]. Additional resources should be committed to
the development and implementation of CRC screening programs to increase uptake in South-
ern Nevada.
Among Nevada’s CRC cases, between 80–90% of each minority population (except Ameri-
can Indian) resided in Southern Nevada, a region shown to be disadvantaged. We found a lack
of racial disparity between non-Hispanic blacks and Filipinos compared to non-Hispanic
whites in Nevada for CRC survival, which runs counter to most other studies conducted in the
US [37–40]. However, given that all racial/ethnic groups in Nevada had lower CRC survival
than their national counterparts, this likely reflects the poor survival of the referent non-His-
panic white group rather than highlighting any notable progress in eliminating disparities for
minorities. A similar absence of black-white survival disparities was previously documented
for both cervical cancer [41] and lung cancer in Nevada [29]. Importantly, while other studies
have consistently documented better CRC survival for the aggregated Asian/Pacific Islander
group compared to non-Hispanic whites [3, 42], our disaggregation of Filipinos as distinct
from Other APIs revealed that Filipinos do not have a survival advantage. Similarly, a previous
study in California among distinct Asian groups found that Filipinos had significantly lower
CRC survival than Chinese, Japanese, and non-Hispanic whites [43]. Thus, Filipinos, especially
those in Southern Nevada, may benefit from targeted and culturally specific CRC prevention
programs, including colon cancer screening.
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Other factors impacting CRC survival in Nevada were consistent with the literature. Sur-
vival was slightly better in the more recent time period. With improvements in treatment
modalities as well as screening detection of tumors at earlier stages, the number of CRC survi-
vors in the US has increased, numbering almost 1.5 million in 2016 [1, 44]. Also consistent
with previous research [45–48], a dose-response relationship was seen between patient SES sta-
tus—previously linked to access to quality medical care, less aggressive treatment and delays in
treatment [49, 50]—and CRC survival in the current study. We also saw better survival for
women, especially those who were married. Several explanations for the survival advantage
[51–53] of women for most cancers have been proposed, including sex-specific differences in
risk factor prevalence, comorbidities and/or health seeking behaviors [52, 53] as well as sex
hormones [54]. Married patients in Nevada, like the US [55–57], had greater survival than sin-
gle, separated, or widowed; this phenomenon is often linked to greater social support, financial
benefits and better health insurance [58, 59]. Lastly, one clinical factor that conferred better
CRC survival was tumor location on the left side of the colon, also previously documented
[60–62].
A major strength of this study is the large sample size provided by the Nevada Central Can-
cer Registry, enabling the creation of stable survival estimates by sex, race/ethnicity, stage of
diagnosis, and region of Nevada for comparison purposes. Matching vital status with the NDI
to completely capture deaths, customarily done in some other states, enhanced the accuracy of
our survival estimates.
Nonetheless, this study is subject to a few limitations. Incompleteness of the data for key
prognostic variables, such as stage at diagnosis, could have influenced the results of this study
[63, 64]. In the sub-analysis, incompleteness of treatment variables precluded assessment of
receipt of stage-appropriate treatment for many patients. Additionally, the quality of treatment
data, especially receipt of chemotherapy and radiation, in cancer registries has not been thor-
oughly assessed across the United States [65, 66]. Individual level data was not available for
SES; our measure by zip code is subject to some degree of ecological fallacy. Registry data does
not include comorbidities, an important determinant of CRC survival; research has shown
that patients with many comorbidities have worse outcomes [67, 68]. However, our use of
cause-specific survival (rather than overall survival) partially compensates for the lack of
comorbidity information. Additionally, we were unable to examine tumor markers and/or
molecular subtypes that negatively influence survival [69]. Individual-level CRC screening
data is not available from registries; we used BRFFS estimates of CRC screening by geographi-
cal area. Lastly, in US cancer registries, foreign-born populations have more missed deaths,
especially in a state like Nevada that uses the “presumed alive” method for censoring [70].
Thus, the survival for groups comprised of many immigrants, including Filipinos, Hispanics,
and Other APIs, may be overestimated.
In conclusion, this study accurately characterized for the first time the colorectal cancer sur-
vival profile in Nevada, revealing disproportionately poor survival compared to the US. We
further identified demographic, social, and clinical factors associated with CRC survival. The
identification of these determinants should help cancer prevention and control efforts,
whether by seeking to intervene on modifiable determinants or providing programming to
specific population groups. Certainly, CRC screening outreach efforts must continue and
expand. A significant disparity between regions of Nevada was identified, disproportionately
impacting rural and Southern Nevada, likely linked to access to care. Further studies are war-
ranted in order to determine the barriers to receipt of stage-appropriate treatment for colorec-
tal cancer patients in Nevada. Collaboratively, all stakeholders, including clinicians and
researchers, must aggressively approach any opportunities not only for primary prevention of
colorectal cancer, but also to maximize the survival potential, at least reaching national levels,
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for all patients who are diagnosed with colorectal cancer in Nevada. Certainly, Nevada should
not have outcomes so vastly disparate from the rest of the American states.
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